Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies

Therapeutic Drug Monitoring

Volumn 35, Issue 5, 2013, Pages 617-623

  Noll, Benjamin D ^a   Coller, Janet K ^b   Somogyi, Andrew A ^b   Morris, Raymond G ^a,b   Russ, Graeme R ^c   Hesselink, Dennis A ^d   Van Gelder, Teun ^d   Sallustio, Benedetta C ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

LC MS MS; renal biopsy; renal transplantation; tacrolimus; tissue tacrolimus concentrations

Indexed keywords

TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALIBRATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG BLOOD LEVEL; ELECTROSPRAY; GRAFT RECIPIENT; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY PARENCHYMA; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIVER; MALE; MASS SPECTROMETER; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RAT; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ANIMALS; BIOPSY; CHROMATOGRAPHY, LIQUID; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LIVER; MALE; RATS; RATS, WISTAR; TACROLIMUS; TANDEM MASS SPECTROMETRY;

EID: 84885018024     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31828e8162     Document Type: Article

References (33)

1. Kho M, Cransberg K, Weimar W, et al. Current immunosuppressive treatment after kidney transplantation. Expert Opin Pharmacother. 2011;12:1217-1231
2. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326-2333
3. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant. 2001;16:1905-1909
4. Bottiger Y, Brattstrom C, Tyden G, et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol. 1999;48:445-448
5. Borobia AM, Romero I, Jimenez C, et al. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit. 2009;31:436-442
6. Balbontin FG, Kiberd B, Squires J, et al. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. Transplant Proc. 2003;35:2445-2448
7. Krejci K, Tichy T, Bachleda P, et al. Calcineurin inhibitor-induced renal allograft nephrotoxicity. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010;154:297-306
8. Haas M, Sonnenday CJ, Cicone JS, et al. Isometric tubular epithelial vacuolization in renal allograft biopsy specimens of patients receiving low-dose intravenous immunoglobulin for a positive crossmatch. Transplantation. 2004;78:549-556
9. Gwinner W, Hinzmann K, Erdbruegger U, et al. Acute tubular injury in protocol biopsies of renal grafts: Prevalence, associated factors and effect on long-Term function. Am J Transplant. 2008;8:1684-1693
10. Sandborn WJ, Lawson GM, Cody TJ, et al. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. Hepatology. 1995;21:70-76
11. Capron A, Lerut J, Verbaandert C, et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: Correlation with histopathologic staging of rejection. Ther Drug Monit. 2007;29:340-348
12. Sandborn WJ, Lawson GM, Krom RA, et al. Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology. 1992;15:1086-1091
13. Hanas E, Tufveson G, Lindgren PG, et al. Concentrations of cyclosporine-A and its metabolites in transplanted human kidney tissue during rejection and stable graft function. Clin Transplant. 1991;5:107-111
14. Noll BD, Coller JK, Somogyi AA, et al. Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies-A method suitable for small (,1 mg) samples. Ther Drug Monit. 2011;33:688-693
15. Yokogawa K, Takahashi M, Tamai I, et al. P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr1a knockout mice. Pharm Res. 1999;16:1213-1218
16. Qin XL, Bi HC, Wang CX, et al. Study of the effect of Wuzhi tablet (Schisandra sphenanthera extract) on tacrolimus tissue distribution in rat by liquid chromatography tandem mass spectrometry method. Biomed Chromatogr. 2010;24:399-405
17. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-Associated protein 2. Am J Transplant. 2005;5:987-994
18. Sallustio BC, Noll BD, Morris RG. Comparison of blood sirolimus, tacrolimus and everolimus concentrations measured by LC-MS/MS, HPLC-UV and immunoassay methods. Clin Biochem. 2011;44:231-236
19. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant. 2008;8:753-760
20. Yu C, Penn LD, Hollembaek J, et al. Enzymatic tissue digestion as an alternative sample preparation approach for quantitative analysis using liquid chromatography-Tandem mass spectrometry. Anal Chem. 2004;76: 1761-1767
21. US FDA. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: CDER; 2001
22. Taylor PJ. Matrix effects: The Achilles heel of quantitative high-performance liquid chromatography-electrospray-Tandem mass spectrometry. Clin Biochem. 2005;38:328-334
23. Bonfiglio R, King RC, Olah TV, et al. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun Mass Spectrom. 1999;13:1175-1185
24. Ceglarek U, Lembcke J, Fiedler GM, et al. Rapid simultaneous quantification of immunosuppressants in transplant patients by turbulent flow chromatography combined with tandem mass spectrometry. Clin Chim Acta. 2004;346:181-190
25. Salm P, Taylor PJ, Rooney F. A high-performance liquid chromatography-mass spectrometry method using a novel atmospheric pressure chemical ionization approach for the rapid simultaneous measurement of tacrolimus and cyclosporin in whole blood. Ther Drug Monit. 2008;30:292-300
26. Seger C, Tentschert K, Stoggl W, et al. A rapid HPLC-MS/MS method for the simultaneous quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human blood samples. Nat Protoc. 2009; 4:526-534
27. Van Eeckhaut A, Lanckmans K, Sarre S, et al. Validation of bioanalytical LC-MS/MS assays: Evaluation of matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:2198-2207
28. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-Associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029-1035
29. Dubbelboer IR, Pohanka A, Said R, et al. Quantification of tacrolimus and three demethylated metabolites in human whole blood using LC-ESI-MS/MS. Ther Drug Monit. 2012;34:134-142
30. Elens L, Capron A, Kerckhove VV, et al. 1199G.A and 2677G.T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics. 2007;17:873-883
31. Zahir H, McCaughan G, Gleeson M, et al. Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation. Ther Drug Monit. 2004;26:506-515
32. Aliabadi HM, Spencer TJ, Mahdipoor P, et al. Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function. AAPS J. 2006;8:E672-E681
33. Kawai R, Mathew D, Tanaka C, et al. Physiologically based pharmacokinetics of cyclosporine A: Extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther. 1998;287:457-468